[New treatments and strategy in multiple sclerosis]

Area of Science:

• Neurology
• Immunology
• Pharmacology

Background:

• Multiple Sclerosis (MS) management has advanced with ten approved therapies for relapsing-remitting MS.
• Four new disease-modifying therapies (DMTs) approved since 2007, with more novel formulations and DMTs nearing commercialization.

Purpose of the Study:

• To review the efficacy and safety of newly approved DMTs for MS.
• To outline current and emerging therapeutic strategies for MS management.

Main Methods:

• Review of pivotal studies for new MS DMTs.
• Analysis of sequential and induction immunotherapy strategies.
• Emphasis on shared decision-making in treatment selection.

Main Results:

• Newer DMTs offer varied efficacy and safety profiles; some are more potent but carry higher risks.
• Self-injectable DMTs, while moderately effective, demonstrate long-term safety and delay disease progression.
• Sequential therapy is standard, with options for switching DMTs based on intolerance or failure.

Conclusions:

• Therapeutic strategies for MS are evolving, balancing efficacy with safety.
• Shared decision-making between patients and neurologists is crucial for treatment adherence.
• Future MS treatment will likely involve personalized approaches based on individual patient needs and disease progression.